Since 2009, we’ve been telling the world about our vision to change clinical trials through technology and data, and scaling up through win-win partnerships.
Today, we’re unveiling the powerful outcome of that vision.
Tomorrow, you’ll wonder why no-one has done this before.
We’ve taken up the colossal task of rewriting the eligibility criteria of every single trial in the world, so that computers can understand that when one study says “T2DM” and another says “diabetes mellitus 2”, they both mean the same thing.
It’s a huge but fundamental task - only with structure can computers play a part in the process, making it faster, more accurate, and opening up a world of further possibilities.
We use cutting-edge technologies to create and optimize our patient-matching algorithm, QBMS (Question-Based Matching Service).
QBMS processes the inclusion/exclusion criteria of all available trials, ranks them by importance, and dynamically generates questions in plain English to help patients find the few trials that truly matter to them.
Patients want to know more than just what trial they match to: What’s the trial about? How long will it take? What will they do to me?
We don’t have the answers to those questions — but you do. So we’ve built a tool that allows you to pass this information to patients, in a format they can relate with. It’s simple, fast, open to everyone, and free.
This tool is in private beta, and you can register your interest here.
To take our vision to a whole new level, we built the world’s first online distribution network dedicated solely to clinical trials and patients.
By joining forces with dozens of communities, advocacy groups, patient portals, blogs, and charities, who reach a combined audience of 100+ million patients per month, we bring the best and latest clinical trial information (including yours) directly to patients.
We’re interested in solutions that work and solutions that scale. Networks do both.
“TrialReach is helping to democratize clinical trials
by bridging the gap between the patients and the researchers
who are developing new medical treatments.”
See our new patient-matching
platform in action.